Invivyd (IVVD) just closed out FY 2025 with fourth quarter revenue of US$17.2 million and a basic EPS loss of US$0.04, alongside net income excluding extra items of a US$11.1 million loss. Over the past few quarters, the company has seen revenue move from US$11.3 million in Q1 2025 to US$13.1 million in Q3 and US$17.2 million in Q4, while quarterly basic EPS moved from a loss of US$0.14 to US$0.06 and then US$0.04. This sets up a results season in which investors are likely to focus on how quickly losses might narrow relative to top line momentum and the implications for margins.

With the headline numbers on the table, the next step is to set these results against the prevailing narratives around Invivyd's growth potential and risk profile to see which investor stories hold up and which start to look stretched.

Losses Shrink On A Trailing Basis

• On a trailing twelve month view, Invivyd reported total revenue of US$53.4 million and a net loss excluding extra items of US$52.5 million, compared with US$25.4 million of revenue and a US$169.9 million loss in the prior trailing period shown.
• Bulls argue this kind of loss compression lines up with their view that earnings could reach US$213.7 million by around 2028. However, the current trailing loss of US$52.5 million and basic EPS of US$0.30 loss still underline how much of that bullish case depends on future margin expansion rather than what is already visible in the recent income statement.
  • The bullish narrative points to profit margins moving from roughly a 238.3% loss today to 48.5% in three years. At the same time, the latest quarterly net loss of US$11.1 million and basic EPS loss of about US$0.04 show the company is still firmly in investment mode.
  • Revenue of US$53.4 million over the last twelve months versus US$36.7 million in the earlier trailing period in the data supports the idea of a growing top line. However, the fact that losses remain over US$50 million means bulls are leaning heavily on future operating leverage rather than current profitability.

Bulls say the recent loss reduction is just the start of a much bigger earnings shift. If you want to see how that story is built across different scenarios, it is worth checking the detailed bull case for Invivyd: 🐂 Invivyd Bull Case

Revenue Growth Versus Bear Concerns

• Across FY 2025, quarterly revenue in the data moves from US$11.3 million in Q1 to US$11.8 million in Q2, US$13.1 million in Q3 and US$17.2 million in Q4, while quarterly net losses excluding extra items range between US$10.5 million and US$16.3 million over the same period.
• Bears focus on regulatory and product concentration risks. However, the combination of rising quarterly revenue and a narrower trailing loss than the US$169.9 million recorded in the earlier period partly pushes back on the idea that the business is stalling, even as it stays dependent on a limited set of antibody programs.
  • Bearish analysts still model very large future revenue growth of 95.5% per year with earnings of US$25.4 million by around 2028, which contrasts with the current trailing loss of US$52.5 million and highlights that even the cautious side expects a meaningful shift from the present run rate.
  • The company remains unprofitable on every quarterly data point provided, which supports bearish worries about ongoing R&D and commercialization costs. However, the gap between a US$60.7 million loss in Q3 2024 and losses closer to US$11 million to US$18 million in recent quarters suggests bears are now watching endurance of this trend more than a simple one way deterioration.

Skeptics point to regulatory and concentration risks, but the earnings path in the data is more nuanced than a simple "all or nothing" story, so it can help to read the detailed bear case to see how those risks are framed: 🐻 Invivyd Bear Case

Valuation Gap And Dilution Trade Off

• Invivyd trades at US$1.74 per share with a P/S of 9.2x, compared with a referenced DCF fair value of about US$105.07 and a US Biotechs industry P/S average of 11.7x and peer average of 5.6x.
• What stands out is how the bullish and cautious narratives both sit alongside a very large modeled DCF gap and a history of substantial shareholder dilution. Anyone looking at that US$105.07 DCF fair value figure needs to balance it against the trailing loss of US$52.5 million and the explicit flag that recent capital raising has already meaningfully added to the share count.
  • The risk and reward summary highlights that losses have been reduced at about 14.6% per year over five years and revenue is forecast to grow 38.7% per year, which can help explain why a model

    Next Steps

    To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Invivyd on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

    See What Else Is Out There

    Invivyd is still running sizeable losses with no profitable quarters in the data, so the story leans heavily on potential margin improvement rather than established resilience.

    If that reliance on turning losses around makes you uneasy, you can quickly compare it with companies that already score well on stability using our 73 resilient stocks with low risk scores and see how a stronger risk profile looks side by side.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.